NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
RAS Mutation · NRAS Gene Mutation · Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jan 2025, none posted yet
Counts until it's fixed
- +5.9
2 insiders sold shares within a month
Since Sep 21, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 36 (final count)
- Started
- May 11, 2022
- Main results expected
- Jan 29, 2025
- Fully finished
- Jan 29, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: Incidence and severity of dose-limiting toxicities (DLTs)
Measured over: First 28 days of treatment
Phase 1b: Incidence and severity of adverse events (AEs)
Measured over: Phase 1b study duration (approximately 1.5 years)
Phase 1b: Change in clinical laboratory abnormalities
Measured over: Baseline through 30 days after end of study treatment
Phase 1b: Change in Eastern Cooperative Oncology Group (ECOG) performance status
Measured over: Phase 1b study duration (approximately 1.5 years)
Phase 2: Objective response rate (ORR)
Measured over: Phase 2 study duration (approximately 3 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-01-29, no fading
- insider_selling_cluster: base 10, now 5.9, since 2026-09-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05340621 · record last updated 2025-03-07 · checked 2026-11-09 15:47 UTC